Dishman Pharma expects a 15% growth in FY12

In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the company’s revenues. Murthy projects the company's growth at 15% in FY12.

September 28, 2011 / 10:45 IST

In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the company

first published: Sep 21, 2011 03:13 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Dishman Pharma expects a 15% growth in FY12

In an interview to CNBC-TV18, Dishman Pharma's chief financial officer VVS Murthy said that the change in rupee would not impact the company’s revenues. Murthy projects the company's growth at 15% in FY12.

DPC02